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Severe oral mucositis occurs frequently in patients receiving hematopoietic stem cell 
transplantation (HCT). Oral mucosal bacteria can be associated with progression of oral 
mucositis, and systemic infection may occur via ulcerative oral mucositis. However, 
little information is available regarding the oral microbiota after HCT. Here, 
PCR-denaturing gradient gel electrophoresis (DGGE) was performed to characterize the 
oral mucosal microbiota, which can be affected by antibiotics, before and after HCT. 
Sixty reduced-intensity HCT patients were enrolled. Three patients with the least 
antibiotic use (quinolone prophylaxis and/or β-lactam monotherapy group) and three 
patients with the most antibiotic use (β-lactam-glycopeptide combination therapy group) 
were selected. Bacterial DNA samples obtained from the oral mucosa before and after 
HCT were subjected to PCR-DGGE. The trajectory of oral mucositis was evaluated. 
The oral mucosal microbiota in the β-lactam-glycopeptide combination therapy group 
was different from that in the quinolone prophylaxis and/or β-lactam monotherapy 
group, and Staphylococcus spp. and Enterococcus spp. were identified. Lautropia 
mirabilis was dominant in one patient. Ulcerative oral mucositis was observed only in 
the β-lactam-glycopeptide combination therapy group. In conclusion, especially with 
the use of strong antibiotics, such as glycopeptides, the oral mucosal microbiota differed 
completely from that under normal conditions, and consisted of Staphylococcus spp., 
Enterococcus spp., and unexpectedly L. mirabilis. The normal oral microbiota consists 
not only of bacteria, but these unexpected bacteria could be involved in the 
pathophysiology as well as systemic infection via oral mucositis. Our results can be 
used as the basis for future studies in larger patient populations. 
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Oral mucositis occurs in approximately 80% of patients receiving high-dose 
chemotherapy as conditioning for hematopoietic stem cell transplantation (HCT) 
(Vera-Llonch et al. 2007). Severe mucositis is associated with not only intolerable pain 
but also the possible risk of systemic bacteremia. Oral mucosal bacteria may play an 
important role in the progression of oral mucositis, as well as systemic infection via oral 
ulcerative mucositis. However, limited information is available regarding the oral 
microbiota after HCT. Streptococci are common components of the oral mucosal flora, 
and therefore streptococcal infection is generally suspected to be of oral origin. 
However, we have encountered a case in which the gingiva in a patient undergoing 
leukemia treatment acted as a site of proliferation and a reservoir for multidrug-resistant 
Stenotrophomonas maltophilia (Soga et al. 2008). We showed that bacterial substitution 
of mainly coagulase-negative staphylococci (CoNS) for streptococci occurred 
frequently on the oral buccal mucosa after HCT by surveillance culture of oral mucosa 
just before and after HCT, and discussed the importance of considering the presence of 
oral mucositis in cases of CoNS infection after HCT (Soga et al. 2011). The oral mucosa 
can be a reservoir of unexpected bacteria because of bacterial substitution due to the use 
of many antibiotics. Indeed, empirical antibacterial management has reduced 
infection-related mortality (Bow 2005), while prophylactic administration of 
fluoroquinolone was reported to induce fluoroquinolone-resistant Escherichia coli 
(Bucaneve et al. 2005; Kern et al. 2005), Pseudomonas aeruginosa (Bucaneve et al. 
2005), Clostridium difficile (Muto et al. 2005; Pepin et al. 2005), etc. Appropriate 
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empirical antibacterial management is important, while another option would be to not 
use antibiotic prophylaxis for supportive care in HCT. 
Many reports regarding bacteria from clinical laboratories were limited to the 
genus level both because of examination capacity and clinical necessity. This strategy 
has limitations to reveal the whole oral mucosal microbiota. Denaturing gradient gel 
electrophoresis (DGGE) introduced by Fisher and Lerman (1983) and Myers et al. 
(1987) for mutation analysis or detection of gene polymorphisms has been widely used 
in microbial ecology (Muyzer et al. 1993). As sequence-specific separation of 16S 
rDNA amplicons of the same length and further sequencing or hybridization analysis 
are possible, DGGE has become a powerful tool to examine bacterial diversity in 
various natural habitats (Muyzer and Smalla 1998), such as marine, lake, and soil 
environments. This method is often employed in medical fields for examination of 
polymicrobial communities in humans (Fujimoto et al. 2003; Muyzer and Smalla 1998; 
Schabereiter-Gurtner et al. 2001). 
The severity of clinically evident mucosal damage increases and peaks between 
6 and 12 days post-HCT, with resolution of uncomplicated mucositis occurring over the 
subsequent 7 – 10 days (Kolbinson et al. 1988; Tardieu et al. 1996). Recently, we 
reported that the severity of oral mucositis was reduced and the peak day of oral 
mucositis was delayed in reduced-intensity stem-cell transplantation (RIST) patients 
compared to those receiving conventional HCT, but almost all patients healed within 2 – 
3 weeks after HCT (Takahashi et al. 2010). Therefore, examining the oral microbiota 
after 1 – 3 weeks of HCT can contribute to determination of bacteria related to the 




This study was performed to determine the changes in the oral mucosal 
microbiota before and after HCT, which would be affected by antibiotic use, using the 
DGGE method, and to provide information on the microbiota associated with 
progression of oral mucositis as well as systemic infection via oral ulcerative mucositis. 
 
 
MATERIALS AND METHODS 
 
Subjects 
A total of 60 consecutive patients (2014-2015) who received HCT at Okayama 
University Hospital because of hematological malignancies were enrolled in this study. 
Oral mucosal bacterial sample collection was performed in all subjects, as described 
below. As DGGE analysis is highly labor intensive, a total of six subjects were chosen 
to evaluate typical changes in the oral mucosal microbiota after HCT, which would be 
affected by antibiotic use. Three patients with the least antibiotic use (quinolone 
prophylaxis and/or β-lactam monotherapy group) and three patients with the most 
antibiotic use (β-lactam-glycopeptide combination therapy group) were selected. The 
groups are summarized in Table 1, and the antibiotics used are summarized in Figure 1. 
All subjects provided informed consent, and the study was approved by the Ethics 
Committee of Okayama University Graduate School of Medicine, Dentistry, and 
Pharmaceutical Sciences (Approval No. 902). 
 
HCT conditioning regimens 
All patients received reduced-intensity stem cell transplantation (RIST). In the majority 
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of cases, reduced-intensity conditioning was performed with a fludarabine-based 
regimen associated with busulfan, melphalan, or cyclophosphamide, as shown in Table 
1. 
  
General infection control 
All patients were isolated in a room equipped with a laminar airflow system. Patients 
received azole drugs or micafungin for prophylaxis against fungal infection. 
Prophylaxis was also given against herpes virus infection with acyclovir. Neutropenic 
fever was managed according to the guidelines of Hughes et al. (2002). Briefly, 
empirical antibiotic therapy was administered promptly in all neutropenic patients at the 
onset of fever and in afebrile patients who were neutropenic but had signs or symptoms 
compatible with infection. The details of the antibiotics administered in each patient are 
shown in Figure 1. G-CSF (lenograstim 5 μg/kg per day or filgrastim 300 μg/m2) was 
given intravenously for 60 min starting on day 1 or 5, and was continued until the 
absolute neutrophil count exceeded 500/μL.  
 
Oral management 
All subjects were referred to dentists, and necessary dental treatment was completed 
before HCT. All subjects received instruction regarding self-management of oral 
hygiene; tooth brushing after every meal and before going to bed, and oral rinsing with 
normal saline solution every 3 h during the day was also indicated. In cases in which the 
patient’s condition was poor, nurses, dental hygienists, and dentists performed these oral 
managements. We usually perform surveillance culture of oral mucosa once per week, 
and antifungal rinses are indicated in cases with the detection of fungi. However, no 
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fungi were detected in these patients, and therefore no antimicrobial rinses were used. 
 
Assessment of oral mucositis 
The severity of oral mucositis in patients undergoing HCT was evaluated every day 
according to the National Cancer Institute Common Terminology Criteria for Adverse 
Events (NCI-CTCAE) version 3.0 
(http://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/ctcaev3.pdf, 
accessed on 31st Dec 2016). The criteria for oral mucositis (clinical exam) were as 
follows: 
Grade 1: Erythema of the mucosa 
Grade 2: Patchy ulcerations or pseudomembranes 
Grade 3: Confluent ulcerations or pseudomembranes; bleeding in response to minor 
trauma 
Grade 4: Tissue necrosis; significant spontaneous bleeding; life-threatening 
consequences 
Grade 5: Death 
As the clinical examination criteria for oral mucositis are no longer included and only 
functional/symptomatic criteria are available in the newest version of NCI-CTCAE 
(4.0), version 3.0 was used to evaluate oral mucositis itself. Assessments were 
performed as part of daily nursing by nurses under the instruction of dentists and dental 
hygienists, and the consistency of assessments was checked during the rounds of 
dentists and dental hygienists at least once per week. 
 




We usually perform surveillance culture from the oral mucosa four times (day –7 to –1; 
day 0 to +6; day +7 to +13; day +14 to +20) in all patients. Microbial samples were 
obtained about 2 h after lunch by swabbing from the whole surface of the buccal 
mucosa regardless of whether mucositis was observed. Culture and identification of 
microorganisms were performed at the Central Clinical Laboratory of Okayama 
University Hospital. Microbial samples from mucosal swabs were plated onto 
Vitalmedia series - sheep blood agar plates (Kyokuto Pharmaceutical Industrial Co., 
Ltd., Tokyo, Japan), and cultured under aerobic conditions at 37°C. Identification of 
colonies thus obtained was performed using matrix-assisted laser desorption ionization–
time of flight mass spectrometry (MALDI-TOF MS) (MALDI Biotyper; Bruker, 
Billerica, MA) according to the manufacturer’s instructions.  
Blood culture was performed when bloodstream infection was suspected using 
the automated VITEK system (SYSMEX; bioMérieux, Marcy l'Etoile, France), and the 
obtained colonies were identified by MALDI-TOF MS (MALDI Biotyper; Bruker) 
according to the manufacturer’s instructions. 
 
Oral mucosal bacterial sample collection and DNA extraction 
Bacterial samples were obtained by gently wiping the buccal mucosa with sterilized 
cotton swabs before (around 1 week) and after (around 2 – 3 weeks) HCT. Samples 
were suspended in 400 μL of PBS (Invitrogen, Carlsbad, CA). Bacterial DNA was 
extracted using a QIAamp® DNA Mini Kit (QIAGEN, Venlo, The Netherlands).  
 




Polymerase chain reaction denaturing gradient gel electrophoresis (PCR-DGGE) 
fingerprinting analysis of 16S rRNA genes was carried out according to Muyzer et al. 
(1993) using the primers GC-341f and 534r with Platinum® PCR SuperMix (Invitrogen 
Ltd., Glasgow, UK). For PCR, we employed a touchdown protocol according to 
Nishijima et al. (2010) with minor modifications; 2 min of Taq DNA polymerase 
activation at 94°C; 20 cycles of denaturation at 94°C for 15 s, annealing at decreasing 
temperature from 65°C to 56°C (1°C decrease for every two cycles) for 15 s, and 
extension at 68°C for 30 s; followed by 15 cycles of 94°C for 15 s, at 55°C for 15 s, and 
at 68°C for 30 s using GeneAmp PCR System 9600 (Applied Biosystems, Foster City, 
CA). For DGGE analyses, the amplicons and DGGE marker I (Nippon Gene, Tokyo, 
Japan) were electrophoresed using a D-code DGGE complete system (Bio-Rad, 
Hercules, CA) operated at 60°C for 12 h at 100 V in a linear 25% – 65% denaturing 
agent gradient (100% denaturing agent consisted of 7 mol/L urea and 40% deionized 
formamide) with 8% polyacrylamide gels [polyacrylamide gel, ratio of acrylamide HG 
(Wako Pure Chemical Industries, Osaka, Japan) to bisacrylamide (Wako Pure Chemical 
Industries), 37.5:1]. After DGGE, the gels were soaked for 30 min in SYBR Green I 
nucleic acid gel stain (1:10000 dilution; Lonza, Rockland, ME) and photographed on a 
UV transilluminator with a CCD camera. 
  
Counting of DGGE bands 
All gels were scanned at 300 dpi. The number of DGGE bands was calculated from the 
densitometric curves of the scanned DGGE profiles with CLIQS ver1.1 software 
(TotalLab Ltd., Newcastle upon Tyne, UK) using the detect band function with the 
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default settings.  
 
Sequence analysis of 16S rRNA gene fragments and homology search 
For sequence determination of DGGE bands, the bands were excised from the gel, and 
the purified DNA was analyzed using an ABI PRISM 3100xl Genetic Analyzer 
(Applied Biosystems) with a BigDye Terminator v3.1 Cycle Sequencing Kit (Applied 
Biosystems) and the primers for the DGGE band sequencing kit for analysis of the 
bacterial v3 region (DS-0001) (TechnoSuruga Laboratory Co., Ltd, Shizuoka, Japan). 
The obtained DNA sequences were subjected to National Center for Biotechnology 
Information (NCBI)-BLAST against the 16S ribosomal RNA sequence (Bacteria and 
Archaea) database (https://blast.ncbi.nlm.nih.gov/Blast.cgi accessed on Dec 31, 2016) 





DGGE profiles of amplified 16S rDNA from mucosal bacterial samples 
PCR-DGGE band patterns representing oral mucosal microbiota before and after HCT 
are shown in Fig. 2. Bands at the same location before and after HCT samples were 
observed in the quinolone prophylaxis and/or β-lactam monotherapy group (especially 
in A1 and A3), while bands were seen at completely different positions between before 
and after HCT samples in the β-lactam-glycopeptide combination therapy group.  
 
Number of DGGE bands and their changes before and after HCT 
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The number of band on DGGE decreased markedly after HCT in the 
β-lactam-glycopeptide combination therapy group: before HCT, 6 – 12 (median: 12); 
after HCT, 4 – 6 (median: 4). The change in number of bands in the quinolone 
prophylaxis and/or β-lactam monotherapy group was slight: before HCT, 17 – 25 
(median: 20); after HCT, 17 – 22 (median: 21). The number of bands after HCT in the 
β-lactam-glycopeptide combination therapy group was decreased compared to that in 
the quinolone prophylaxis and/or β-lactam monotherapy group. 
 
Bacteria composing the oral mucosal microbiota before and after HCT 
The bacterial species identified from the major bands on DGGE are shown in Table 2. 
Band sequence analysis of 16S rRNA gene fragments and homology search were 
performed as described in the previous section, and in cases where the BLAST search 
result was 100% identity with multiple bacterial species, all are described in this table. 
All identified bacteria had > 99% identity. 
As shown in Table 2A, in the quinolone prophylaxis and/or β-lactam 
monotherapy group, Streptococcus spp. were frequently identified in samples from both 
before and after HCT, which was correlated with the results of surveillance oral mucosal 
culture, as shown in Table 3. A number of bacteria considered to be components of the 
normal oral microbiota, such as Gemella spp., Veillonella spp., Rothia spp., and 
Actinomyces spp., were also identified although they were not detected by surveillance 
culture. Bacteria not detected by surveillance culture were revealed by sequencing of 
PCR-DGGE bands. 
Almost all bacteria identified in the quinolone prophylaxis and/or β-lactam 
monotherapy group could be explained as normal oral microbiota, while bacteria that 
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are not usually components of the normal oral microbiota, such as Staphylococcus spp. 
and Enterococcus spp., were identified after HCT in the β-lactam-glycopeptide 
combination therapy group, which was correlated with the results of surveillance oral 
mucosal culture as shown in Table 3. Interestingly, Lautropia mirabilis, which is rare, 
was newly identified only recently (Gerner-Smidt et al. 1994), and was not detected by 
the culture method, was dominant in one patient. 
 
Trajectory of oral mucositis  
The trajectories of oral mucositis in each patient are shown in Figure 3. There were no 
cases in which oral mucositis was suspected to be caused by acute graft versus host 
disease, and all were induced by the conditioning regimen for HCT. Oral mucositis in 
all patients in the quinolone prophylaxis and/or β-lactam monotherapy group (A1 – A3) 
was less than grade 1 or zero (limited to redness), while all patients in the 
β-lactam-glycopeptide combination therapy group (B1 – B3) reached grade 2 
(ulcerative oral mucositis) around day 7 – 19. Blood culture was performed when 
ulcerative mucositis appeared only once for patient B2 on day 7, and Streptococcus 
agalactiae was identified. This species was also detected in oral surveillance culture 





The oral mucosal microbiota changed rapidly after HCT and was completely different 
from that before HCT in the β-lactam-glycopeptide combination therapy group. Many 
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antibiotics are used clinically to prevent infections in highly compromised patients, and 
therefore such changes in the microbiota can occur in many cases of HCT. The observed 
decrease in number of bands in the β-lactam-glycopeptide combination therapy group 
indicated antibiotic selection, and bacteria corresponding to the bands after HCT could 
be strongly resistant to antibiotics. Bacteria that are not normal components of the oral 
microbiota, such as Staphylococcus spp., Enterococcus spp., and Lautropia mirabilis, 
were shown to be involved in the pathophysiology of oral mucositis after HCT (Table 
2B). Interestingly, all cases of ulcerative mucositis (> grade 2) occurred in the 
β-lactam-glycopeptide combination therapy group, and the normal oral microbiota 
disappeared. Our observations suggested that unusual microbiota could lead to 
progression of oral mucositis. Furthermore, positive blood culture for S. agalactiae was 
also detected in oral surveillance when ulcerative mucositis appeared in one case, and 
therefore infection via oral mucositis was suspected. 
While we reported previously that bacterial substitution of mainly 
coagulase-negative staphylococci (CoNS) for streptococci occurred frequently on the 
oral buccal mucosa after HCT based on surveillance culture of oral mucosa just before 
and after HCT (Soga et al. 2011), Enterococcus spp. were identified after HCT in the 
β-lactam-glycopeptide combination therapy group. Enterococci are part of the normal 
human microbial flora, and are common inhabitants of the human gastrointestinal (GI) 
tract. Although these species normally constitute a small proportion of the gut 
microbiota (Eckburg et al. 2005), an important first step toward nosocomial 
enterococcal infection seems to be increased density of colonization of the GI tract 
(Arias and Murray 2012). The present study showed that oral mucosal microbiota after 
HCT with antibiotic treatment could be similar to the conditions in the GI tract, and that 
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oral mucositis could be associated with enterococcal bacteremia. 
Unexpectedly, L. mirabilis was detected in one subject as one of the major 
bacteria composing the oral microflora after HCT. L. mirabilis, a motile gram-negative 
coccus characterized in 1994, has been isolated from oral and pulmonary sites 
(Gerner-Smidt et al. 1994). Rossmann et al. reported a significant association of L. 
mirabilis isolation with human immunodeficiency virus (HIV) infection in 1998 
(Rossmann et al. 1998). Recent microarray analyses have detected L. mirabilis in the 
subgingival microbiota of periodontally healthy subjects (Colombo et al. 2012; 
Colombo et al. 2009), and it was shown to be most abundant in the subgingival 
microbiota of healthy children (Shaddox et al. 2012). There have been few studies 
regarding the pathogenicity of L. mirabilis, and this is the first report of L. mirabilis as a 
dominant species in the oral mucosa. In patient B2, only two bands were clear after 
HCT, with the clearest being L. mirabilis. Unexpected bacteria, such as L. mirabilis, 
could be involved in the pathophysiology of oral mucositis after HCT. Furthermore, oral 
mucositis after HCT could be a route of infection for unusual bacteria, such as L. 
mirabilis. 
The oral mucosa after HCT is a reservoir of unusual bacteria, which may be 
involved in the pathophysiology of oral mucositis, and systemic infection may occur via 
ulcerative oral mucositis. The pathogenic effects of bacteria composing the mucosal 
microbiota and bacterium–epithelial interactions may play important roles in the 
progression of oral mucositis, and be involved in systemic infection via ulcerative oral 
mucositis. Especially, strong antibiotic therapy causes remarkable selection of 
microbiota in the oral mucosa, and therefore candidate bacteria that should be studied 
with regard to their roles in oral mucositis could appear. Clinically, we would like to 
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emphasize the importance of intensive oral care focusing on the oral mucosa in patients 
undergoing HCT. 
DGGE is a powerful tool to examine bacterial diversity (Muyzer and Smalla 
1998), but it is highly labor intensive and difficult to perform. The small number of 
subjects (limited to six subjects) represented a limitation of this study. However, it was 
unavoidable with use of the DGGE method, while we observed clear changes in the oral 
mucosal microbiota in the β-lactam-glycopeptide combination therapy group before and 
after HCT, and showed that Staphylococcus spp., Enterococcus spp., and unexpectedly 
L. mirabilis were candidates for future studies regarding management of oral mucositis 
and infection via oral mucositis after HCT. Molecular technology is rapidly advancing, 
and newly developed techniques will provide further clear information regarding 
changes in the oral mucosal microbiota. The results presented here can be used as a 
basis for future studies.  
Whether there is an association between these microorganisms and the 
development and/or presence of ulcerative mucositis could be determined in future 
studies in a larger patient population and with more sampling points. Other factors, such 
as the level and duration of neutropenia, and local oral factors, such as changes in the 
quantity and composition of saliva, may also influence alterations in the microbiome. In 
addition, in vitro studies using an experimental mucositis model could yield further 
insights.  
In conclusion, we demonstrated changes in the oral mucosal microbiota before 
and after HCT by the DGGE method, which were affected by the use of antibiotics. 
Especially with the use of strong antibiotics, such as glycopeptides, the oral mucosal 
microbiota differed completely from that seen under normal conditions, and consisted of 
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Staphylococcus spp., Enterococcus spp., and unexpectedly L. mirabilis. The normal oral 
microbiota consists not only of bacteria, but these unexpected bacteria could be 
involved in the pathophysiology of oral mucositis as well as systemic infection via oral 
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Figure 1. Summary of antibiotics used and the timing of sample collection 
Antibiotics used in each patients and the timing of sample collection are shown. LVFX: 
levofloxacin; SMX/TMP: sulfamethoxazole/trimethoprim; TEIC: teicoplanin; MEPM: 
meropenem; VCM: vancomycin; CLDM: clindamycin; CFPM: cefepime; DAP: 
daptomycin. The top three subjects are defined as the quinolone prophylaxis and/or 
β-lactam monotherapy group, and the bottom three subjects are defined as the 
β-lactam-glycopeptide combination therapy group. The timings of mucosal bacteria 
sample collection are also shown by arrows (before HCT: white arrows; after HCT: 
black arrows). Double lines show the days of engraftment. 
 
Figure 2. DGGE profiles of amplified 16S rDNA from mucosal bacterial samples of 
HCT patients 
DGGE profiles of amplified 16S rDNA from mucosal bacterial samples of HCT patients 
are shown. (A) Quinolone prophylaxis and/or β-lactam monotherapy group. (B) 
β-Lactam-glycopeptide combination therapy group. bfr: before HCT sample; aft: after 
HCT sample. Intense bands (A: a – ao, B: a – z) were sequenced, and bacterial species 
identified from the sequence data are shown in Table 2. M: marker. 
 
Figure 3. Trajectory of oral mucositis  
The trajectories of oral mucositis in all patients are shown. Oral mucositis of all patients 
in the quinolone prophylaxis and/or β-lactam monotherapy group (A1 – A3) was < 
grade 1 or zero (limited to redness), while that in all patients in the 
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β-lactam-glycopeptide combination therapy group (B1 – B3) reached grade 2 





Table 1. Summary of the subjects 
Group patient age sex disease type of HCT day of engraftment after HCT 
Quinolone prophylaxis and/or 
β-lactam monotherapy group 
A1 69 F AML with MRC ur-BMT (RIST, Flu+BU) 19 
A2 71 F MDS ur-BMT (RIST, Flu+Mel+TBI 2Gy) 15 
A3 19 F CAEBM CBT (RIST, Flu+CY+TBI 2Gy) 21 
β-lactam-glycopeptide 
combination therapy group 
B1 67 M AML ur-PBSCT (RIST, Flu+BU+TBI 2Gy) 15 
B2 61 F AML ur-BMT (RIST, Flu+Mel+TBI 2Gy) 20 
B3 64 M AML with MRC ur-BMT (RIST, Ful+BU+CA) 20 
 
AML: acute myelogenous leukemia; MRC: myelodysplastic syndrome (MDS)-related changes; MDS: myelodysplastic syndrome; CAEBM: chronic 
active EB virus infection; ur-PBSCT: unrelated peripheral blood stem cell transplantation; ur-BMT: unrelated bone marrow transplantation; CBT: cord 
blood stem cell transplantation; RIST: reduced-intensity stem cell transplantation; TBI: total-body irradiation; Flu: fludarabine; BU: busulfan; Mel: 
melphalan; CY: cyclophosphamide; CA: cytarabine 




Table 2. Bacterial species identified from major bands of DGGE  
(A) Quinolone prophylaxis and/or β-lactam monotherapy group 
Pt. A1  Pt. A2  Pt. A3 
bfr  aft  bfr  aft  bfr  aft 
band identified 
bacterial species 
 band identified 
bacterial species 
 band identified 
bacterial species 
 band identified 
bacterial species 
 band identified 
bacterial species 

















 m Gemella 
taiwanensis or 
haemolysans 




 n Gemella 
taiwanensis or 
haemolysans 
            





       y Granulicatella 
adiacens 

















 o Streptococcus 
dentisani, 
oralis, mitis, 
       ac Streptococcus 
sinensis, 
pharyngis, 




















































 t Veillonella 
tobetsuensis, 
rogosae or dispar 
    ad Veillonella 
tobetsuensis, 
rogosae or dispar 










 u Veillonella 
atypica 
    ae Veillonella 
tobetsuensis, 
rogosae or dispar 






    v Veillonella 
atypica 
         
i Veillonella 
atypica 
               






 r Rothia 
mucilaginosa 
 w Rothia 
mucilaginosa 
 z Rothia 
mucilaginosa 
      
l Rothia 
dentocariosa 
       aa Actinomyces 
odontolyticus 
 af Rothia 
dentocariosa 




          ag Actinomyces 
odontolyticus 
   
 
 








         
 
In cases in which the results of BLAST search showed 100% identity with multiple bacterial species, all are shown in this table. 




(B) β-Lactam-glycopeptide combination therapy group 
Pt. B1  Pt. B2  Pt. B3 
bfr  aft  bfr  aft  bfr  aft 
band identified 
bacterial species 
 band identified 
bacterial species 
 band identified 
bacterial species 
 band identified 
bacterial species 
 band identified 
bacterial species 




















               




















   i Enterococcus 
faecalis 








































      k Veillonella 
tobetsuensis, 
rogosae or dispar 
    u Veillonella 
tobetsuensis, 
rogosae or dispar 
   
      l Capnocytophaga 
leadbetteri 









    m Veillonella 
tobetsuensis and 
dispar 
    w Veillonella 
rogosae 









         




         
      p Eubacterium sulci          
      q Leptotrichia 
hofstadii 
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         s Lautropia 
mirabilis 
      
e Rothia 
mucilaginosa 
               
f Rothia 
dentocariosa 
               
 
In cases in which the results of BLAST search showed 100% identity with multiple bacterial species, all are shown in this table. 




Table 3. Identified bacteria by surveillance oral mucosal culture 
(A) Quinolone prophylaxis and/or β-lactam monotherapy group 
Pt. A1  Pt. A2  Pt. A3 





 α-Streptococcus sp. 
Stomatococcus sp. 
 α-Streptococcus sp. 
Stomatococcus sp. 
γ-Streptococcus sp. 
 α-Streptococcus sp. 
Stomatococcus sp. 
 α-Streptococcus sp. 
Corynebacterium sp. 
Neisseria sp. 





(B) β-Lactam-glycopeptide combination therapy group 
Pt. B1  Pt. B2  Pt. B3 




 Enterococcus sp. 
CoNS 
 α-Streptococcus sp. 
Stomatococcus sp. 
γ-Streptococcus sp. 
 CoNS  α-Streptococcus sp. 
 
 Enterococcus sp. 
CoNS  
CoNS: coagulase-negative Staphylococcus sp. 
 
 
